In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

The Medicaid State Drug Utilization Data lacked diagnosis codes that would have helped determine the clinical appropriateness of each glucagon prescription. One author was supported by a grant ...